Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
AN2 Therapeutics, Inc. | Director | Common Stock | 485K | $9.27M | $19.11 | Jan 12, 2024 | Indirect |
AN2 Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 64.5K | Jun 19, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ANTX | AN2 Therapeutics, Inc. | Jun 19, 2024 | 1 | $0 | 4 | Jun 21, 2024 | Director |
ANTX | AN2 Therapeutics, Inc. | Jan 12, 2024 | 2 | -$31.2K | 4 | Jan 17, 2024 | Director |
ANTX | AN2 Therapeutics, Inc. | Jan 10, 2024 | 2 | -$80.4K | 4 | Jan 12, 2024 | Director |
ANTX | AN2 Therapeutics, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
ANTX | AN2 Therapeutics, Inc. | May 12, 2022 | 1 | $0 | 4 | May 16, 2022 | Director |
ANTX | AN2 Therapeutics, Inc. | Mar 29, 2022 | 10 | $2.3M | 4 | Mar 31, 2022 | Director |
ANTX | AN2 Therapeutics, Inc. | Mar 24, 2022 | 0 | $0 | 3 | Mar 24, 2022 | Director |